1. Home
  2. MFM vs BNR Comparison

MFM vs BNR Comparison

Compare MFM & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFS Municipal Income Trust

MFM

MFS Municipal Income Trust

N/A

Current Price

$5.41

Market Cap

223.2M

Sector

Finance

ML Signal

N/A

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

N/A

Current Price

$22.85

Market Cap

252.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MFM
BNR
Founded
1986
2014
Country
United States
China
Employees
N/A
N/A
Industry
Finance Companies
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
223.2M
252.7M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
MFM
BNR
Price
$5.41
$22.85
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
67.5K
13.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
4.08%
N/A
EPS Growth
N/A
N/A
EPS
0.03
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$136.32
Revenue Next Year
N/A
N/A
P/E Ratio
$182.33
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.94
$2.18
52 Week High
$5.67
$41.72

Technical Indicators

Market Signals
Indicator
MFM
BNR
Relative Strength Index (RSI) 35.68 40.29
Support Level $5.35 $19.72
Resistance Level $5.47 $24.23
Average True Range (ATR) 0.06 1.74
MACD -0.02 -0.29
Stochastic Oscillator 0.04 27.09

Price Performance

Historical Comparison
MFM
BNR

About MFM MFS Municipal Income Trust

MFS Municipal Income Trust is a diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax, but it may also consider capital appreciation. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in municipal bonds.

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

Share on Social Networks: